Patents by Inventor David Harden

David Harden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted piperidine compounds useful as modulators of chemokine receptor activity
    Publication number: 20050250792
    Abstract: The invention provides compounds of formula (I): wherein R1, R2, R3, R6, Z, Q, m, n, X1, X2, X3, X4 and T are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy, especially for the treatment of chemokine receptor related diseases and conditions.
    Type: Application
    Filed: March 16, 2005
    Publication date: November 10, 2005
    Inventors: Stephen Thom, Andrew Baxter, Nicholas Kindor, Thomas McInally, Brian Springthorpe, Matthew Perry, David Harden, Richard Evans, David Marriott
  • Substituted piperidine compounds useful as modulators of chemokine receptor activity
    Patent number: 6903085
    Abstract: The invention provides compounds of formula (I) wherein R1, R2, R3, R6, Z, Q, m, n, X1, X2, X3, X4 and T are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy, especially for the treatment of chemokine receptor related diseases and conditions
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: June 7, 2005
    Assignee: AstraZeneca, AB
    Inventors: Stephen Thom, Andrew Baxter, Nicholas Kindor, Thomas McInally, Brian Springthorpe, Matthew Perry, David Harden, Richard Evans, David Marriott
  • Tablet formulation
    Patent number: 4209513
    Abstract: A tablet suitable for use in the treatment of microbial infections, which tablet comprises from 80 to 98% (w/w) of a combination of a 2,4-diaminopyrimidine with a sulphonamide and not more than 20% (w/w) of both a granulating and a disintegrating agent, the combination having a particle size less than 40 .mu.m and the disintegrating agent having a swelling capacity greater than 5 ml/g.
    Type: Grant
    Filed: April 14, 1978
    Date of Patent: June 24, 1980
    Assignee: Burroughs Wellcome Co.
    Inventors: Allan J. Torode, David Harden, John Spence